Insofar as NVS is contractually entitled to appoint three directors to IDIX’s BoD, I presume that NVS will soon name a replacement for Projan.
In the same 8-K filing, IDIX disclosed that general counsel, John Weidenbruch, is leaving effective 8/31/10 to work for another biotech company in Cambridge, MA whose identity has not been disclosed.